NICE says yes and no to Amgen's Xgeva
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, maintains that Amgen's Xgeva (denosumab) would not be cost-effective for preventing skeletal-related events in adults with bone metastases from prostate cancer on the National Health Service. However, according to today's final appraisal determination, it still looks set to recommend the drug for preventing SREs in other patients.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.